Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216387 | 1.00 | ADRB3 (0.60) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL2216392 | 1.00 | ADRB3 (0.60) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL12018617 | 1.00 | ADRB3 (0.60) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL8249196 | 1.00 | ADRB3 (0.60) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL12358253 | 0.93 | ADRB3 (0.53) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL2242886 | 0.92 | CTSB (0.58) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL2242905 | 0.92 | CTSB (0.58) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL12018579 | 0.92 | CTSB (0.58) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL2242894 | 0.92 | CTSB (0.58) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL16315740 | 0.90 | ADRB3 (0.68) | ADRB3ADRA2BADRA2CCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2B6, SRD5A1, NR5A2 | ADRB3 894/4885ADRA2B 1835/4885ADRA2C 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.